100 related articles for article (PubMed ID: 20372838)
1. Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue.
Waalkes S; Simon P; Hennenlotter J; Knapp J; Tezval H; Serth J; Stenzl A; Kuczyk MA; Merseburger AS
Oncol Rep; 2010 May; 23(5):1257-60. PubMed ID: 20372838
[TBL] [Abstract][Full Text] [Related]
2. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
Merseburger AS; Hennenlotter J; Simon P; Müller CC; Kühs U; Knüchel-Clarke R; Moul JW; Stenzl A; Kuczyk MA
Oncol Rep; 2006 Jul; 16(1):79-83. PubMed ID: 16786126
[TBL] [Abstract][Full Text] [Related]
3. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.
Schmitz M; Grignard G; Margue C; Dippel W; Capesius C; Mossong J; Nathan M; Giacchi S; Scheiden R; Kieffer N
Int J Cancer; 2007 Mar; 120(6):1284-92. PubMed ID: 17163422
[TBL] [Abstract][Full Text] [Related]
4. Cellular interactions of the phosphorylated form of AKT in prostate cancer.
Hammerich KH; Frolov A; Li R; Ittmann M; Ayala GE
Hum Pathol; 2017 May; 63():98-109. PubMed ID: 28300578
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
[TBL] [Abstract][Full Text] [Related]
6. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of Phospholipase Cε (PLCε) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer.
Wang X; Fan Y; Du Z; Fan J; Hao Y; Wang J; Wu X; Luo C
Med Sci Monit; 2018 Jan; 24():254-263. PubMed ID: 29330357
[TBL] [Abstract][Full Text] [Related]
8. PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas--implications for Akt activation.
Hennenlotter J; Ohneseit PA; Simon P; Merseburger AS; Serth J; Kuehs U; Kramer M; Hartmann JT; Stenzl A; Kuczyk MA
Oncol Rep; 2008 May; 19(5):1141-7. PubMed ID: 18425369
[TBL] [Abstract][Full Text] [Related]
9. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.
Dreher T; Zentgraf H; Abel U; Kappeler A; Michel MS; Bleyl U; Grobholz R
Virchows Arch; 2004 Jun; 444(6):509-17. PubMed ID: 15118854
[TBL] [Abstract][Full Text] [Related]
10. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.
Jendrossek V; Henkel M; Hennenlotter J; Vogel U; Ganswindt U; Müller I; Handrick R; Anastasiadis AG; Kuczyk M; Stenzl A; Belka C
BJU Int; 2008 Aug; 102(3):371-82. PubMed ID: 18476967
[TBL] [Abstract][Full Text] [Related]
11. Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.
Ko YH; Miyake H; Behnsawy HM; Cheon J; Fujisawa M
Urol Int; 2014; 93(2):146-51. PubMed ID: 24556942
[TBL] [Abstract][Full Text] [Related]
12. Expression of mTOR signaling pathway markers in prostate cancer progression.
Kremer CL; Klein RR; Mendelson J; Browne W; Samadzedeh LK; Vanpatten K; Highstrom L; Pestano GA; Nagle RB
Prostate; 2006 Aug; 66(11):1203-12. PubMed ID: 16652388
[TBL] [Abstract][Full Text] [Related]
13. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
14. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
Breen KJ; O'Neill A; Murphy L; Fan Y; Boyce S; Fitzgerald N; Dorris E; Brady L; Finn SP; Hayes BD; Treacy A; Barrett C; Aziz MA; Kay EW; Fitzpatrick JM; Watson RWG
Prostate; 2017 Sep; 77(12):1288-1300. PubMed ID: 28726241
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Thomas GV; Horvath S; Smith BL; Crosby K; Lebel LA; Schrage M; Said J; De Kernion J; Reiter RE; Sawyers CL
Clin Cancer Res; 2004 Dec; 10(24):8351-6. PubMed ID: 15623612
[TBL] [Abstract][Full Text] [Related]
16. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
van Duijn PW; Trapman J
Prostate; 2006 May; 66(7):749-60. PubMed ID: 16425184
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
De Marzo AM; Meeker AK; Epstein JI; Coffey DS
Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
20. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
